Almaral is proud to announce a significant milestone reached by Marginum, a Finnish health-tech company specializing in advanced optical tissue recognition technology. In a groundbreaking clinical study at Tampere University Hospital, this innovative technology was used for the first time in the world during brain tumor surgery.
The technology allows neurosurgeons to receive real-time data on tissue characteristics, enabling more precise removal of tumor tissue and improving patient outcomes. By integrating fluorescence markers, the device differentiates tumor cells from healthy tissue and provides audio feedback, enhancing surgical precision beyond traditional visual methods.
Marginum, with support from Almaral, aims to bring this advanced technology to the international market, opening new avenues for safer, more effective cancer surgeries.